AIDS-defining opportunistic illnesses in the HAART era in New York City.

Despite widespread availability of HAART, opportunistic illnesses (OIs) still occur and result in an increased risk of mortality among persons with AIDS. We estimated the incidence of OIs among all new adult AIDS cases in New York City in 2000 overall and in demographic and clinical subgroups and identified factors associated with occurrence of an AIDS-defining OI versus AIDS diagnosis based on low CD4+ values only. In 2000, 5,451 new AIDS cases were reported to the New York City Department of Health and Mental Hygiene. Of these 27.4% (95% CI: 22.8-32.6) had at least one OI, most frequent being Pneumocystis jiroveci pneumonia (12.2%) and M. tuberculosis (5.3%); 47.1% (41.7-52.5) had a late HIV diagnosis (i.e.< or =6 months before AIDS diagnosis). Persons with a late HIV diagnosis not in recent care had a 3.5-fold increased odds (1.29-9.63) of an OI, compared to non-late testers in care. Other predictors of an OI were injection drug use and older age. We conclude that OIs remain prevalent in the HAART era and late testers not in care are especially likely to develop an OI. Our results support comprehensive HIV programs promoting early HIV testing and linkage to care to prevent OI-related morbidity and mortality.

Trends in immunologic and clinical status of newly diagnosed HIV-positive patients initiating care in the HAART era.

OBJECTIVE: To evaluate whether the availability of highly active antiretroviral therapy (HAART) has motivated people at risk for HIV infection to be tested earlier. METHODS: Data are from the Adult and Adolescent Spectrum of HIV Disease (ASD) Study, a chart review study of HIV-infected people receiving care. The sample comprised newly diagnosed HIV-positive persons initiating care at five ASD clinics in New York City (NYC) 1994 to 1999. CD4 + lymphocyte count and clinical status (asymptomatic, major AIDS-related symptoms, AIDS-defining opportunistic illnesses) at first visit were ascertained. Trends in these two outcomes were analyzed comparing each time period after the second half of 1996 with the aggregate period from 1994 to the first half of 1996. RESULTS: Between 1994 and 1999, we identified 545 patients newly diagnosed as positive for HIV with a first visit to an ASD clinic. Patients were predominantly black or Hispanic (93%). The mean CD4 + count at baseline was 246 cells/microl and the median was 152 cells/microl. After adjusting for covariates, the mean CD4 + count of newly diagnosed HIV-positive patients was significantly lower ( p =.04) only during the second half of 1997. The proportion of patients who were asymptomatic at baseline ranged from 29% in the second half of 1998 to 61% in the first half of 1994 (chi 2 = 48.8; p =.0008). After adjustment for covariates, the probability of a patient having a major symptom or an opportunistic illness at baseline was significantly higher only during the second half of 1998 ( p =.001). DISCUSSION: During most time periods, both before and after the introduction of HAART, most newly diagnosed patients at these five HIV clinics in NYC were immune suppressed and symptomatic.

TB prevention in HIV clinics in New York City.

SETTING: Ten hospital-based human immunodeficiency virus (HIV) clinics in New York City. OBJECTIVE: To evaluate tuberculosis (TB) prevention in HIV clinics based on the prevalence and incidence of TB and the efficacy of preventive therapy with isoniazid (INH). DESIGN: The medical records of 2393 HIV-infected patients with a first clinic visit in 1995 were reviewed retrospectively. Deaths and TB cases through December 1997 were ascertained through a match with the TB and AIDS registries. RESULTS: At first visit, 92 patients (4%) had a history of TB, 98 (4%) were being treated for TB, and six (<1%) were diagnosed with TB. During follow-up, 23 cases were diagnosed, an incidence of 0.53 per 100 person-years (py) (95%CI 0.34-0.77). Among 439 tuberculin skin test (TST) positive patients, the incidence of TB/100 py was 1.63 (95%CI 0.27-5.02) in patients with no INH, 1.28 (95%CI 0.40-2.98) in patients with <12 months of INH, and 1.06 (95%CI 0.38-2.28) in patients with 12 months of INH. The incidence/100 py was 0.0 (95%CI 0.0-0.78) in TST-negative patients and 0.37 (95%CI 0.09-0.95) in anergic patients. The relative risk of TB was 0.65 (95%CI 0.14-4.56) in TST-positive patients with 12 months of INH (vs. none). CONCLUSIONS: The benefits of TB prevention efforts in these HIV clinics from 1995 to 1997 were limited because most TB occurred before the first clinic visit. Methods for reaching HIV-infected patients earlier should be identified.

Trends in prescriptions for highly active antiretroviral therapy in four New York City HIV clinics.

OBJECTIVE: To describe trends in prescriptions for antiretroviral therapies and factors associated with prescriptions for highly active antiretroviral therapy (HAART). METHODS: Medical records of patients at four HIV clinics in New York City were reviewed every 6 months. For the four 6-month periods 1997 to 1998, we identified patients with a CD4+ nadir <500 cells/microl; sample sizes were 434, 432, 503, and 643, respectively. Trends in HAART prescriptions were tested by logistic regression using robust variance estimates because some patients contributed more than one time period. Associations between HAART prescriptions and patient characteristics were tested by chi2 and multiple logistic regression analysis. RESULTS: Patients were predominantly black or Hispanic (89%-90%) and male (66%-68%), and injection drug use was the most prevalent HIV risk (38%-49%). From 1997 to 1998, HAART prescriptions increased from 54% to 89% of antiretroviral prescriptions, and the proportion that included an nonnucleoside reverse transcriptase inhibitors (NNRTI) increased from 3% to 10%. HAART prescriptions were inversely associated with CD4+ nadir group during all time periods, and in the second half of 1998, patients with CD4+ nadir between 50 and 199 cells/microl were as likely to be prescribed HAART as the most immunosuppressed patients (CD4+ nadir <50 cells/microl; 91% versus 92%). HAART prescriptions were associated with clinic, HIV risk, and other patient characteristics in some time periods but not consistently. CONCLUSIONS: In these four HIV clinics, prescriptions for HAART increased significantly from 1997 to 1998, leveling off at 89% in the second half of 1998. Increasingly, HAART was prescribed for healthier patients and included an NNRTI.

Prophylaxis for opportunistic infections among HIV-infected patients receiving medical care.

In 1995 and 1997, the United States Public Health Service (USPHS) and the Infectious Disease Society of America (IDSA) published recommendations for primary prophylaxis of Pneumocystis carinii pneumonia (PCP), Mycobacterium avium complex (MAC), and toxoplasmosis in HIV-infected adults. We evaluated their implementation at four hospital-based HIV clinics in New York City in patients who initially met the CD4+ criterion for prophylaxis between January, 1995 and April, 1997. Medical records were reviewed at 6-month intervals to determine drugs prescribed. We identified 149 patients for the PCP sample, 130 for MAC, and 138 for toxoplasmosis. In the three samples, 91% were black and Hispanic, 75% to 81% were male, and 43% to 47% had a history of injection drug use (IDU); median age was between 39 and 40 years. PCP prophylaxis was prescribed during 93% of intervals and did not vary significantly by clinic or patient characteristics. Over the study period, MAC prophylaxis increased from 22% to 62%, and prescriptions for macrolides increased from 38% to 87% of all prescriptions. In the logistic regression analysis, prescription for MAC prophylaxis at any time during the study period was less likely in blacks compared with whites (odds ratio [OR] = .08; 95% confidence interval [CI] = .01, .52) and patients attending the clinic with the lowest rate of MAC prophylaxis (clinic D) compared with the clinic with the highest rate (clinic B; OR = .04; 95% CI = .01, .26). Toxoplasmosis prophylaxis was prescribed in 73% of intervals and did not differ significantly by antibody status (p = .42). Prescribing patterns were uniform across gender, HIV risk behavior, and age for PCP and MAC prophylaxis but differed by clinic and race for MAC prophylaxis. Trends in prophylaxis for opportunistic illnesses must continue to be monitored in light of the success of antiretroviral therapy in reducing the morbidity and mortality associated with HIV/AIDS.

Purified protein derivative testing and tuberculosis preventive therapy for HIV-infected patients in New York City.

OBJECTIVE: To determine whether Centers for Disease Control and Prevention recommendations for purified protein derivative (PPD) testing and tuberculosis (TB) preventive therapy for PPD-positive patients are implemented in HIV clinics. DESIGN: Retrospective medical chart review. SETTING: Ten hospital-based HIV clinics in New York City. PARTICIPANTS: A total of 2397 patients with a first clinic visit in 1995. OUTCOME MEASURES: PPD testing of eligible patients, and recommendation of preventive therapy and completion of regimen in PPD-positive patients. METHOD: Outpatient medical records were abstracted for TB history, PPD testing, TB preventive therapy, and patient demographic, social and clinical characteristics. Multivariate analyses were performed using logistic regression. RESULTS: Of 1342 patients with an indication for a PPD test, 865 (64%) were PPD tested in the clinic and 757 (88%) returned to have it read. Factors strongly associated with PPD testing in the clinic were number of visits, same sex behavior with men, and CD4+ lymphocyte count above 200 x 10(6)/l. Preventive therapy was recommended for 80% of newly identified PPD-positive patients and 22% of previously identified PPD-positive patients. Of 119 patients on preventive therapy in the clinic, 49 (41%) completed the regimen, 50 (42%) were lost to follow-up, and 20 (17%) discontinued therapy or their status could not be determined. CONCLUSION: A significant number of missed opportunities to implement TB prevention practices were identified in HIV clinics. Focused attention in HIV clinics, and increased collaboration between HIV clinics and TB control programs may be needed to increase adherence to prevention guidelines.

HIV risk behaviors among adolescents at a sexually transmitted disease clinic in New York City.

PURPOSE: The purpose of this study was to describe human immunodeficiency virus (HIV)-associated risk behaviors among adolescents attending a clinic for the treatment of sexually transmitted disease in New York City. METHODS: A total of 4,585 volunteers were interviewed and HIV-tested, including 456 adolescents (aged 13-19 years), of whom 220 were women (48%) and 236 men (52%). RESULTS: Fewer than 1% of the 456 adolescents said they injected drugs. Unprotected vaginal sex was the most common sexual behavior, with 93% of adolescents reporting "always" having vaginal sex, and 57% "rarely or never" using condoms. Anal sex was reported by 18%. Twenty percent of adolescent men had paid for sex, compared to just 1% of women, whereas 3% of men and 4% of women had traded sex for money or drugs. Nine women and three men tested HIV seropositive. All three HIV-positive men reported having had receptive anal sex with men. Among women, HIV seropositivity was most strongly associated with crack cocaine use and trading sex for money or drugs. CONCLUSIONS: HIV prevalence was high, with most infections owing to sexual transmission rather than intravenous drugs. The increased risk of HIV infection in adolescent women was associated with high-risk sex related to crack use and the exchange of sex for money or drugs.

Previous use of oral contraceptives and spontaneous abortion.

This analysis tests the hypothesis that women who conceive within 3 months after stopping oral contraceptives ("the pill") have an intrinsically lower risk of chromosomally normal loss. About 30% of women show evidence of endocrine dysfunction, including anovulation, for 1-3 months after stopping the pill. In women who recover rapidly, and therefore are at risk of pregnancy, a common endocrinologic factor may account for both the quick return to normal functioning and improved intrauterine survival of the chromosomally normal conceptus. The hypothesis was tested in women with chromosomally normal (N = 334) and chromosomally aberrant (N = 239) spontaneous abortions. Women were classified according to the number of months between last pill use and last menstrual period. The adjusted odds ratios relating conception in months 0 and 1 after stopping the pill to chromosomally normal (vs chromosomally aberrant) loss were each 0.4, with upper 95% confidence limits of 1.0 and 0.9, respectively. The odds ratios for conception at longer intervals after stopping were 1.1 [95% confidence interval (CI) = 0.4-3.1], 0.7 (95% CI = 0.3-1.2), and 0.9 (95% CI = 0.5-1.5) for 2, 3-11, and > or = 12 months, respectively. Rates of spontaneous abortion in previous pregnancies were lowest in women who conceived quickly after stopping the pill. Further support for an endocrinologic explanation requires direct measures of endocrine functioning in the post-pill period among women with varying reproductive histories.